Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

TOF Mass Spectrometer

By Drug Discovery Trends Editor | September 2, 2008

Bruker Daltonics maXisThe maXis from Bruker Daltonics is an Electrospray Ultra-High Resolution tandem TOF (UHR-Qq-TOF) mass spectrometer for applications including small molecule identification, metabolomics, quantitative proteomics, as well as biomarker discovery and validation.

The maXis offers ultra-high resolution of 40,000 – 60,000 FWHM over a broad mass range, MS and MS/MS mass accuracy typically between 600 and 800 ppb, at speeds of up to 20 full spectra per second.  It also offers 20 Hz full spectra acquisition at ultra-high mass resolution for high-speed liquid      chromatography; novel IonCooler technology delivers excellent MS/MS sensitivity over a broad m/z range; high dynamic range of five orders of magnitude for trace detection in complex mixtures; sub-ppm mass accuracy in both MS and MS/MS mode for high confidence IDs; and SmartFormula 3D unambiguous determination of molecular sum formulae for molecules up to 1 kDalton.

“Now ultra-high resolution mass spectrometry over broad mass ranges is finally compatible with ultra performance liquid chromatography,” explained Bruker Daltonics Executive Vice President Dr. Ian Sanders. “Our new maXis indeed represents a major step forward in tandem mass spectrometry, offering a no-compromise solution for exceptional accurate mass, ultra-high resolution over a broad mass range and high sensitivity MS and MS/MS analysis at a speed able to take full advantage of modern, fast liquid chromatography or fast capillary electrophoresis separations.”

Bruker Daltonics


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE